CHLOROQUINE PHOSPHATE

Search structure


Trade Names:	ARALEN CHLOROQUINE PHOSPHATE
Synonyms:	ARALEN ARECHIN AVLOCLOR CHLOROQUINE DIPHOSPHATE CHLOROQUINI PHOSPHAS MALAQUIN MALARIVON NSC-14050 RESOCHIN SN-7618 WR-1522
Status:	Approved (1949)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	6E17K3343P
Parent Compound:	CHLOROQUINE

Structure


InChI Key	AEUAEICGCMSYCQ-UHFFFAOYSA-N
Smile	CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O
InChI	InChI=1S/C18H26ClN3.H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);(H3,1,2,3,4)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H32ClN3O8P2
Molecular Weight	515.87
AlogP	4.81
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	8.0
Polar Surface Area	28.16
Molecular species	BASE
Aromatic Rings	2.0
Heavy Atoms	22.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Ferriprotoporphyrin IX inhibitor	PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6	-	-	-	-	20.4
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4	-	-	-	-	6.8
Enzyme Protease Metallo protease Metallo protease MAE clan Metallo protease M27 family	-	-	-	-	6.51-7
Enzyme Transferase	-	-	-	-	24.58
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-43.27--7.2
Epigenetic regulator Writer Protein methyltransferase SET domain	-	-	4700	-	-
Other cytosolic protein	-	5900000	-	-	36.9-97.4
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC02 family of hexose and sugar alcohol transporters	-	-	-	-	1.44
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	84.34
Transporter	-	-	-	-	1.44

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Arthritis, Rheumatoid	3	D001172	ClinicalTrials
Atrial Fibrillation	2	D001281	ClinicalTrials
Lupus Erythematosus, Systemic	2	D008180	ClinicalTrials
Severe Acute Respiratory Syndrome	2	D045169	ClinicalTrials
Pneumonia, Viral	2	D011024	ClinicalTrials
Severe Acute Respiratory Syndrome	2	D045169	ClinicalTrials
HIV Infections	2	D015658	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Cardiac disorders	10.89
Nervous system disorders	10.42
Psychiatric disorders	10.15
Injury, poisoning and procedural complications	9.29
General disorders and administration site conditions	7.42
Investigations	6.91
Respiratory, thoracic and mediastinal disorders	5.89
Eye disorders	5.78
Musculoskeletal and connective tissue disorders	4.8
Vascular disorders	4.22
Metabolism and nutrition disorders	3.4
Gastrointestinal disorders	3.32
Blood and lymphatic system disorders	3.08
Immune system disorders	3.01
Skin and subcutaneous tissue disorders	2.93
Infections and infestations	2.89

Cross References

Resources	Reference
ChEBI	3638
ChEMBL	CHEMBL58510
EPA CompTox	DTXSID7044681
FDA SRS	6E17K3343P
Guide to Pharmacology	5535
KEGG	C07625
PDB	CLQ
PubChem	64927
SureChEMBL	SCHEMBL40827
ZINC	ZINC01530861

CONTENTS